[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Lifespan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":145},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,80,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100053892","early-phase-1-digital-intervention-delivered-via-street-medicine-to-increase-hiv-and-substance-use-care-among-survivors-of-sex-trafficking-100053892",false,"NCT07699484","Digital Intervention Delivered Via Street Medicine to Increase HIV and Substance Use Care Among Survivors of Sex Trafficking","Digital Intervention Delivered Via Street Medicine to Increase HIV and Substance Use Care Among Survivors of Sexual Trafficking","1. Age 18 years and above at enrollment\n2. Woman\n3. Screen positive for lifetime sexual trafficking","FEMALE","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","The goal of this clinical trial is to learn if the CONNECT program helps women with a history of sex trafficking get connected to substance use, HIV\u002FSTI, and mental health services. It will also learn whether the program is practical to deliver and acceptable to participants. The main questions it aims to answer are:\n\nDoes CONNECT increase participants' engagement in substance use treatment (such as starting medication for opioid use disorder or therapy for alcohol use), HIV and STI prevention and treatment services (such as starting PrEP or getting tested for STIs), and mental health treatment (such as treatment for PTSD)? Is CONNECT feasible and acceptable for women with a history of sex trafficking?\n\nResearchers will compare CONNECT to usual care to see if CONNECT increases engagement in these health services. The program will be delivered in partnership with a Street Medicine team that provides care directly to unhoused women, with support from a trained care navigator.\n\nParticipants will:\n\nComplete the CONNECT program or receive usual care Work 1:1 with a care navigator who helps with referrals to substance use, HIV\u002FSTI, and mental health services (CONNECT group) Complete assessments at the start of the study and at a 2-month follow-up Answer questions about their substance use, health behaviors, mental health, and use of health services",[26,27,28,29,30,31],"Sex Trafficking","HIV","Substance Use (Drugs, Alcohol)","Mental Health","Sexual Violence","Treatment Engagement",[26,27,33,29,30,31],"Substance Use","NOT_YET_RECRUITING","2026-07-07",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":20},"2026-10-05",{"date":42,"type":20},"2028-06-30",{"name":44,"class":45},"Lifespan","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":46},"100583775","phase-4-injectable-buprenorphine-in-prison-a-preference-trial-100583775","NCT06880718","Injectable Buprenorphine in Prison: A Preference Trial","Injectable Buprenorphine During Transition Out of Prison: A Partially Randomized Preference Pilot Trial","Inclusion Criteria:\n\n1. be at least 18 years of age and incarcerated in the RIDOC facility,\n2. be currently diagnosed with OUD and enrolled in the RIDOC MOUD program,\n3. have an expected release date within 120 days of study enrollment,\n4. have an interest in XR-B and\n5. be English speaking\n\nExclusion Criteria:\n\n1. individuals who are pregnant or planning conception,\n2. diagnosed with a severe or acute medical or psychiatric disability preventing safe study participation or making follow-up unlikely,\n3. have a release date within 21 days of initiation, or\n4. have previously had an allergy to buprenorphine. Post-enrollment exclusion will include individuals if there is a change in release date beyond the 120 days and therefore no longer meet original inclusion criteria. These individuals would return to usual MOUD care.","ALL",{"count":19,"type":20},[57],"PHASE4","The goal of this pilot trial is to compare two branded extended-release buprenorphine (XR-B) formulations (Sublocade vs. Brixadi) to explore how they improve treatment retention after release from prison among incarcerated individuals with opioid use disorder (OUD) who are transitioning back into the community.\n\nThe main question it aims to answer are:\n\nHow do Sublocade and Brixadi compare in terms of feasibility, acceptability, and effectiveness? Does giving people a choice of medication affect how well they stay in treatment?\n\nUsing a partially randomized preference trial approach, there will be a comparison between participants who choose their XR-B formulation to those who are randomly assigned to see if patient preference influences treatment outcomes. The trial is a hybrid implementation-effectiveness trial.\n\nParticipants will:\n\n* Choose which medication they prefer or be randomly assigned if they don't have a preference.\n* Receive monthly injections of either Sublocade or Brixadi before and after release from prison.\n* Complete surveys and clinical assessments on treatment experience and acceptability.\n* Be monitored for treatment retention, opioid use, and adverse events for six months post-release.\n\nResearchers will compare the two treatments to see which one works better for people leaving prison and if allowing people to choose their treatment improves results.",[60,61,62,63],"Opioid Use Disorder","Incarceration","Medications for Opioid Use Disorder","Buprenorphine",[65,66,67,68,69,70],"opioid use disorder","incarceration","prison","long-acting injectable","buprenorphine","XR-B","RECRUITING","2026-05-13",{"date":74,"type":38},"2026-05-15",{"date":76,"type":38},"2026-02-18",{"date":78,"type":20},"2027-06",{"name":44,"class":45},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":16,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":91,"briefSummary":93,"conditions":94,"keywords":103,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":46},"100578015","stress-reactivity-and-mother-infant-cardiovascular-disease-risk-100578015","NCT06805799","Stress Reactivity and Mother-Infant Cardiovascular Disease Risk","Maternal-Infant Stress Reactivity as an Intergenerational Pathway to Cardiovascular Disease Risk","Inclusion Criteria:\n\n* For the parent RCT study: Inclusion criteria: singleton pregnancy, English speaking, \\>18 years old, \\\u003C20 weeks' gestation at enrollment, normotensive at enrollment, and criteria consistent with 'moderate' to 'high' risk for preeclampsia based on American College of Obstetrician and Gynecologist guidelines. For the current research study: Participants will be (n=40) individuals from the parent RCT who have consented to be contacted for future research in the parent study and are not pregnant during the mentored research study procedures.\n\nExclusion Criteria:\n\nFor the parent RCT study: Exclusion criteria: multiple gestations; chronic hypertension; active suicidality or psychosis; ongoing mind-body practice (e.g., yoga, meditation, mindfulness \\> once a week).\n\n\\-",true,"6 Months",{"count":90,"type":20},40,[92],"NA","Prenatal Mindfulness training (MT) shows promise as a preventive intervention against hypertensive disorders of pregnancy (HDP) and may reduce risk for offspring cardiovascular disease (CVD). One proposed mechanism of MT to reduced CVD risk is improved self-regulation following stress. Perhaps the most crucial contributor to the development of self-regulation in the first year is the psychophysiological coregulatory relationship between mother and infant. However, this self-and co-regulation among women exposed to prenatal MT has not been studied and has yet to be examined in relation to CVD risk. The goal of this proposed project is to evaluate maternal-infant physiological reactivity to and recovery from stress at 6 months postpartum following prenatal MT, and to examine the relationship between these maternal infant stress responses and maternal-infant CVD risk at 12 months postpartum.\n\nUsing a lab-based stress paradigm and well-validated biomarkers of mother and infant CVD risk, the investigators will assess respiratory sinus arrhythmia and heart rate at 6 months postpartum for 40 mother-infant dyads who have completed either prenatal MT or a usual care arm of an RCT examining MT for women at risk for HDP. The investigators will compare maternal, infant, and dyadic stress responses by treatment arm. Then, cardiac stress responses will be examined as predictors of maternal and infant biomarkers of CVD risk at 12 months postpartum.",[95,96,97,98,99,100,101,102],"Maternal Health","Infant Health","Hypertension","Behavioral Medicine","Mindfulness","Psychophysiology","Cardiovascular Diseases","Cardiovascular Diseases Risk",[99,100,104,105,106,97],"Coregulation","Maternal-infant Coregulation","Cardiovascular Disease Risk","2026-03-31",{"date":109,"type":38},"2026-04-01",{"date":111,"type":20},"2026-04-15",{"date":113,"type":20},"2026-07-31",{"name":44,"class":45},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":21,"phases":124,"briefSummary":125,"conditions":126,"keywords":130,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":46},"100589366","phase-4-implementing-low-barrier-hcv-treatment-in-a-jail-setting-100589366","NCT06953479","Implementing Low-Barrier HCV Treatment in a Jail Setting","MINMON-J: An Effectiveness Implementation Pilot Study Evaluating a Low-barrier Hepatitis C Treatment Model in a Jail Setting","MINMON-J","Inclusion Criteria:\n\n* Incarcerated individual at RIDOC\n* Age ≥ 18 years\n* Awaiting trial (i.e., not sentenced)\n* English speaking\n* Diagnosis of active HCV (HCV RNA \\>1000 IU\u002FmL within 90 days prior to study entry)\n* Treatment-naïve for current HCV infection\n* No cirrhosis (FIB-4 Score \\\u003C3.25 within 90 days prior to study entry)\n* Self-report of injection drug use\n* Ability and willingness to be contacted after jail release\n* Verbal commitment to continue medication after discharge\n* Desire to receive Sofosbuvir\u002FVelpatasvir (Epclusa)\n\nExclusion Criteria:\n\n* Cirrhosis (FIB-4 Score \\>3.25 within 90 days prior to study entry and\u002For clinical signs of cirrhosis)\n* Positive for Hepatitis B surface antigen\n* Actively pregnant or breastfeeding\n* Known allergy\u002Fsensitivity to study drug components\n* Acute or serious illness requiring hospitalization at enrollment\n* Documented severe persistent mental illness (SPMI) by RIDOC\n* Any clinical history of hepatic decompensation (e.g., ascites, SBP, HE, HRS, variceal bleeding)\n* HIV-positive with active or acute AIDS-defining opportunistic infection within 90 days",{"count":90,"type":20},[57],"The goal of this clinical trial is to learn whether a low-barrier treatment program can help people with hepatitis C virus (HCV) who are in jail start and complete treatment more easily. This study focuses on adults at the Rhode Island Department of Corrections who have active HCV and are awaiting trial.\n\nThe study asks:\n\n* Can a simplified, low-barrier HCV treatment program work in a jail setting?\n* Do participants finish treatment and get cured using this approach?\n\nAll participants will receive a 12-week course of the HCV medication sofosbuvir\u002Fvelpatasvir (Epclusa). If they are released before completing treatment, they will take the remaining doses with them. Community Health Workers (CHWs) will help support participants after release, including reminding them to take medications and helping them get follow-up lab work.\n\nResearchers will measure:\n\n* Whether participants are cured of HCV\n* Whether the treatment approach is easy to use (feasible), acceptable, and followed correctly (fidelity)\n* Whether the program could be used in other jails or expanded in the future\n\nThis study may help bring HCV treatment to more people in jail, reduce community spread of the virus, and support national goals to eliminate HCV.",[127,61,128,129],"HEPATITIS C (HCV)","Injection Drug Use","Implementation Science",[131,66,132,133,134,135,136],"hepatitis c","jail","injection drug use","minimal monitoring","MINMON","implementation science","2026-02-26",{"date":139,"type":38},"2026-02-27",{"date":141,"type":38},"2025-06-11",{"date":143,"type":20},"2027-08",{"name":44,"class":45},""]